# EDGAR Filing Document

**Accession Number:** 0001858685
**File Stem:** 0001641172-25-013491
**Filing Date:** 2025-6
**Character Count:** 9508
**Document Hash:** 6797b5efbff8b22056a002c9a5847a9d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-013491.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001641172-25-013491

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250603

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biofrontera Inc.
- **CENTRAL INDEX KEY:** 0001858685
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473765675
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40943
- **FILM NUMBER:** 251020798

**BUSINESS ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801
- **BUSINESS PHONE:** 781-245-1325

**MAIL ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): June 3, 2025**

**Biofrontera Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40943** | **47-3765675** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **120 Presidential Way, Suite 330**<br> **Woburn, Massachusetts** | **01801** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (781) 245-1325**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common stock, par value $0.001 per share** | **BFRI** | **The Nasdaq Stock Market LLC** |
| **Preferred Stock Purchase Rights** |  | **The Nasdaq Stock Market LLC** |
| **Warrants to purchase common stock** | **BFRIW** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act") (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01** **Other Events.**

On June 3, 2025, Biofrontera Inc. (the "Company") filed a supplement (the "Supplement") to its Proxy Statement filed with the Securities and Exchange Commission on April 30, 2025 to revise the initial disclosure in the Proxy Statement regarding what happens when a stockholder does not vote on a proposal. A copy of the Supplement is filed as Exhibit 99.1 to this Current Report on Form 8-K. The Company encourages all stockholders to review the Proxy Statement and the Supplement and to vote their shares on all proposals presented at the annual meeting.

**Item 9.01** **Financial Statements and Exhibits.**

99.1 [Supplement to Proxy Statement, dated June 3, 2025](ex99-1.htm) <br> 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **June 3, 2025**<br>|  | **Biofrontera Inc.**<br>|
| (Date) |  | (Registrant) |
|  | By: | */s/ E. Fred Leffler III* |
|  |  | E. Fred Leffler III |
|  |  | *Chief Financial Officer* |

---

## Exhibit 99.1

**Exhibit 99.1**

**SUPPLEMENT DATED JUNE 3, 2025**

**TO THE PROXY STATEMENT FOR**

**THE 2025 ANNUAL MEETING OF STOCKHOLDERS OF BIOFRONTERA INC.**

**To Be Held on June 12, 2025**

**Explanatory Note**

On April 30, 2025, Biofrontera Inc. (the "Company") filed a Proxy Statement (the "Proxy Statement") with the Securities and Exchange Commission in connection with the Company's 2025 Annual Meeting of Stockholders to be held June 12, 2025, at 10:00 a.m., Eastern Time (the "Meeting").

After the filing of the Proxy Statement, the Company was advised that the New York Stock Exchange ("NYSE") has determined that Proposal Nos. 2 and 3 included in the Proxy Statement are considered "routine" matters under NYSE rules, meaning that banks, brokers and other nominees have authority to vote shares held in street name on Proposal Nos. 2 and 3 without receiving voting instruction from the beneficial owner of such shares. This determination differs from the disclosure in the Proxy Statement, which indicated that only Proposal No. 4 in the Proxy Statement was a "routine" matter and, therefore, banks, brokers and other nominees would not have the authority to vote shares held in street name on Proposal Nos. 2 and 3 without receiving voting instructions from the beneficial owner of such shares. Accordingly, this supplement to the Proxy Statement is being filed to revise our initial disclosure in the Proxy Statement regarding what happens when a stockholder does not vote on Proposal Nos. 2 and 3.

The answer under the heading "Questions and Answers – What happens if I do note vote?" on page 4 of the Proxy Statement is hereby amended and restated as follows:

---

| | |
|:---|:---|
| **Q:** | ***What happens if I do not vote?*** |
| A: | *Stockholder of Record: Shares Registered in Your Name* |
|  | If you are a stockholder of record and do not vote in person or proxy by returning a proxy card or submitting your proxy through the internet or by telephone, your shares will not be voted. |
|  | *Beneficial Owner: Shares Registered in the Name of Broker or Bank* |
|  | If you are a beneficial owner and do not instruct your broker, bank, or other agent how to vote your shares, your broker or nominee will be able to vote your shares only on proposals that are "routine" matters. At the Meeting, approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 35,000,000 to 70,000,000 (Proposal No. 2), approval of a proposal to adjourn the Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Share Increase Proposal (Proposal No. 3), and the ratification of the appointment of our independent registered public accounting firm (Proposal No. 4) are each considered a "routine" matter. However, we understand that certain brokerage firms have elected not to vote even on "routine" matters without your voting instructions. If your bank, broker or other nominee has made this decision, and you do not provide voting instructions, your shares will not be voted at the Annual Meeting. Accordingly, we urge you to direct your bank, broker or other nominee how to vote by returning your voting materials as instructed or by obtaining a legal proxy from your broker or other nominee in order to vote your shares electronically at the Annual Meeting. This ensures that your shares will be voted at the Meeting in the manner you desire. |

---

Other than the revised language above, no other changes have been made to the Proxy Statement, and the Company's Board of Directors continues to seek the vote of Company stockholders to be voted on at the Meeting as recommended in the original Proxy Statement. As a stockholder, your vote is very important, and the Board encourages you to exercise your right to vote whether or not you plan to attend the Annual Meeting.

Proxies already received will continue to be voted as instructed unless otherwise revoked or changed by a subsequent proxy.

**EXCEPT AS DESCRIBED IN THIS SUPPLEMENT, THE INFORMATION PROVIDED IN THE PROXY STATEMENT REMAINS UNCHANGED. TO THE EXTENT THAT INFORMATION IN THIS SUPPLEMENT DIFFERS FROM OR UPDATES INFORMATION CONTAINED IN THE PROXY STATEMENT, THE INFORMATION IN THIS SUPPLEMENT IS MORE CURRENT. THE PROXY STATEMENT CONTAINS ADDITIONAL INFORMATION. THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.**